

1 PATIENT INFORMATION Patient Name: _____ Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ MRN #: _____ DOB: _____ Drug Allergies: _____	2 PRESCRIBER INFORMATION Prescriber's Name: _____ DEA#: _____ NPI: _____ Clinic/Facility Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____
3 Instructions to Provider All orders with ✓ will be placed unless otherwise noted. Please fax completed order form to 206-326-2139. For drug prior authorization, call 1-888-767-4670 or visit https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/preservice .	
4 CLINICAL INFORMATION Diagnosis (ICD-10 code): _____ Date of Last Dose: _____	
5 TOCILIZUMAB PRESCRIPTION INFORMATION Tocilizumab-aazg (TYENNE) in 0.9% Sodium Chloride IV Injection Route: Intravenous TB Status: <input type="checkbox"/> PPD (negative) Date: _____ <input type="checkbox"/> Last Chest X-Ray: Date _____ <input type="checkbox"/> Active TB: <input type="checkbox"/> Unknown First Dose: <input type="checkbox"/> No <input type="checkbox"/> Yes Weight: _____ kg Date Recorded: _____ Dose & Frequency: _____ mg/kg x weight (kg) once every _____ weeks Refills: <input type="checkbox"/> 11 months <input type="checkbox"/> Other _____ Infusion Access: <input type="checkbox"/> PIV <input type="checkbox"/> CVAD <input type="checkbox"/> Other: _____ Patient's Current Home Care/Specialty Pharmacy: _____ • For patients with RA, GCA, COVID-19, CRS, PJIA, and SJIA patients at or above 30 kg, dilute to 100 mL in 0.9% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique. • For PJIA, SJIA and CRS patients less than 30 kg, dilute to 50 mL in 0.9% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique. • Administer as a single intravenous infusion over 60 minutes; do not administer as bolus or push. Max 800mg. Infusion Reaction Medications & Supplies <div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <input checked="" type="checkbox"/> Hydrocortisone sodium succinate injectable 100 mg IV Sig: Once PRN for hypersensitivity <input checked="" type="checkbox"/> Epinephrine Auto-Injector <input type="checkbox"/> 0.15mg <input type="checkbox"/> 0.3mg QTY: 2 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use. <input checked="" type="checkbox"/> Sodium Chloride 0.9% IV Flush: Flush 10 ml IV before/after medication administration or as needed for line maintenance </div> <div style="width: 48%;"> <input checked="" type="checkbox"/> Diphenhydramine injectable 25 mg IV Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath <input checked="" type="checkbox"/> Sodium Chloride 0.9% IV 250 ml Bag Sig: Once PRN for anaphylaxis </div> </div> Labs /Special Instructions/Pre-meds: _____ _____ _____	
Infusion Protocol: <ul style="list-style-type: none"> Infuse per manufacturer guidelines Monitor vital signs (Temp, BP, HR, RR) every 15 minutes x 4; then every 30 minutes x2; then every 60 minutes until completion of infusion Documentation must include: <ul style="list-style-type: none"> Start and end time of infusion All rate changes, vital signs, including initial and final set Patient response 	<ul style="list-style-type: none"> Observe patient for signs of infusion rate-related adverse reactions: <ul style="list-style-type: none"> Blood pressure changes, increased pulse rate Fever, chills Headache Chest, back or hip pain Dyspnea Mild erythema
6 PHYSICIAN SIGNATURE REQUIRED	
X _____ SUBSTITUTION PERMITTED (Date)	X _____ DISPENSE AS WRITTEN (Date)

CONFIDENTIALITY NOTICE: This message and any attached files might contain confidential information protected by federal and state law. The information is intended only for the use of the individual(s) or entities originally named as addressees. The improper disclosure of such information may be subject to civil or criminal penalties. If this message reached you in error, please contact the sender and destroy this message. Disclosing, copying, forwarding, or distributing the information by unauthorized individuals or entities is strictly prohibited by law.

Members with Medicare Part B or D coverage are not required to use this form.